254 filings
Page 5 of 13
DEFA14A
we7m8sa ws
23 Apr 21
Additional proxy soliciting materials
4:33pm
8-K
uewnvtkgi89932
30 Mar 21
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
6:01am
8-K
ghmh twpm
8 Mar 21
Regulation FD Disclosure
8:38am
S-8
l8ar3u5jd74ma
1 Mar 21
Registration of securities for employees
4:31pm
8-K
q1q4p2ymnfau
25 Feb 21
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
4:10pm
8-K
xxba0z
28 Dec 20
Regulation FD Disclosure
8:35am
8-K
p9i7vp9l
9 Nov 20
Cara Therapeutics Reports Third Quarter 2020 Financial Results
4:10pm
8-K
6eulhtd
20 Oct 20
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
6:30am
8-K
rdn8m
1 Oct 20
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
5:17pm
8-K/A
1sk4al 5ksxf7
11 Aug 20
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
hcu1pgx5tkzg3whvu
10 Aug 20
Cara Therapeutics Reports Second Quarter 2020 Financial Results
4:10pm
8-K
i4vu7iqwqpy0ejfpne4
30 Jun 20
Departure of Directors or Certain Officers
7:18am
8-K
mn42x2nc9i9n582kv9oa
17 Jun 20
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with KARE Phase 2 Trial Design
7:11am
8-K
ikld uvn8rgg
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
v0cththsy3gi5 pgy
11 May 20
Cara Therapeutics Reports First Quarter 2020 Financial Results
4:10pm